INT10344

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.73
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 23
Total Number 23
Disease Relevance 6.36
Pain Relevance 7.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Jun) nucleus (Jun) DNA binding (Jun)
transcription factor binding (Jun)
Anatomy Link Frequency
sciatic nerve 1
lung 1
Jun (Mus musculus)
Pain Link Frequency Relevance Heat
Sciatic nerve 2 99.98 Very High Very High Very High
Morphine 30 99.96 Very High Very High Very High
Oxycodone 14 99.96 Very High Very High Very High
tramadol 166 99.90 Very High Very High Very High
tolerance 7 99.56 Very High Very High Very High
Pain 168 99.50 Very High Very High Very High
potassium channel 1 98.94 Very High Very High Very High
headache 3 98.74 Very High Very High Very High
Cancer pain 20 98.56 Very High Very High Very High
Analgesic 39 98.38 Very High Very High Very High
Disease Link Frequency Relevance Heat
Stress 21 100.00 Very High Very High Very High
Atherosclerosis 35 99.38 Very High Very High Very High
Cancer 156 98.74 Very High Very High Very High
Repression 13 98.60 Very High Very High Very High
Cancer Pain 21 98.56 Very High Very High Very High
Hypoxia 68 98.06 Very High Very High Very High
Sprains And Strains 183 98.00 Very High Very High Very High
Incontinence 4 97.80 Very High Very High Very High
Osteoarthritis 22 96.96 Very High Very High Very High
Pain 197 95.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Of them, Twik-1, coding for a potassium channel, was associated with tolerance, and JunB and Nur77, members of an immediate early gene family and of the nuclear receptor family respectively, had an increased expression that persisted a long time after alcohol ingestion [73].
Localization (members) of immediate early associated with tolerance, potassium channel and alcohol
1) Confidence 0.73 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691669 Disease Relevance 0.07 Pain Relevance 0.52
This model, which uses a human proenkephalin-beta-galactosidase fusion gene, readily permits anatomic and cellular colocalization of stress-regulated immediate early gene products (e.g.
Localization (colocalization) of immediate early associated with stress
2) Confidence 0.68 Published 1994 Journal Mol. Endocrinol. Section Abstract Doc Link 8170480 Disease Relevance 0.58 Pain Relevance 0
The review suggested that immediate-release and controlled-release preparations of oxycodone have similar efficacy and comparable side effect profiles.
Localization (release) of immediate-release associated with oxycodone
3) Confidence 0.51 Published 2002 Journal Pharmacotherapy Section Abstract Doc Link 12126222 Disease Relevance 0.07 Pain Relevance 0.97
and c-Jun (a phosphorylation target of ERK and JNK).
Localization (target) of c-Jun
4) Confidence 0.43 Published 2004 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1082887 Disease Relevance 0.18 Pain Relevance 0
We compared the effects of controlled-release and immediate-release morphine preparations in adult patients with moderate-to-severe cancer pain and report methodologic approaches to pain evaluation.
Localization (release) of immediate-release associated with pain, cancer pain and morphine
5) Confidence 0.42 Published 1992 Journal J Pain Symptom Manage Section Abstract Doc Link 1484191 Disease Relevance 0.66 Pain Relevance 1.05
INTERVENTIONS: Controlled-release oxycodone tablets given every 12 hours; immediate-release oxycodone tablets given four times daily; dose titration with controlled-release or immediate-release for up to 10 days; double-blind treatment for 4-7 days each.
Localization (release) of immediate-release
6) Confidence 0.42 Published 1999 Journal Clin J Pain Section Body Doc Link 10524470 Disease Relevance 0.08 Pain Relevance 0
The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine.
Localization (release) of immediate-release associated with pain, cancer, analgesic and morphine
7) Confidence 0.42 Published 1992 Journal J Pain Symptom Manage Section Title Doc Link 1484191 Disease Relevance 0.95 Pain Relevance 1.80
In one study, the pharmacokinetics of intravenous, oral immediate-release and oral extended-release (OROS®) formulations were compared.
Localization (release) of immediate-release
8) Confidence 0.39 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697506 Disease Relevance 0 Pain Relevance 0.14
B are activated in the lung after asbestos exposure (Haegens et al. 2007; Janssen et al. 1997; Mossman et al. 2000) and that MCP-1 is important in the initiation of atherosclerosis (Gosling et al. 1999), distal changes in AP-1 and NF-?
Localization (changes) of AP-1 in lung associated with atherosclerosis
9) Confidence 0.32 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2535625 Disease Relevance 0.50 Pain Relevance 0.08
Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
Localization (release) of immediate-release associated with headache
10) Confidence 0.22 Published 2007 Journal J Clin Pharmacol Section Title Doc Link 17322147 Disease Relevance 0.19 Pain Relevance 0.10
A specific example is a study demonstrating that Sirt1 deacetylation of AP1 modulates its function and causes repression of the Cox2 gene [19].
Localization (deacetylation) of AP1 associated with repression
11) Confidence 0.21 Published 2010 Journal J Ovarian Res Section Body Doc Link PMC2831895 Disease Relevance 0.45 Pain Relevance 0
The order of predominance for the different TREs was: cRel, v-Myb, CRE-BP1/c-Jun, USF, AP-1_Q2, Pax-6, AP-1_C, NF-kappaB_Q6, Efr-1, Egr-3, and AREB6 (Figure 6 and Table 1 [additional file 1]).


Localization (was) of AP-1_C
12) Confidence 0.19 Published 2007 Journal BMC Urol Section Body Doc Link PMC1888709 Disease Relevance 0 Pain Relevance 0
The order of predominance for the different TREs was: cRel, v-Myb, CRE-BP1/c-Jun, USF, AP-1_Q2, Pax-6, AP-1_C, NF-kappaB_Q6, Efr-1, Egr-3, and AREB6 (Figure 6 and Table 1 [additional file 1]).


Localization (was) of c-Jun
13) Confidence 0.19 Published 2007 Journal BMC Urol Section Body Doc Link PMC1888709 Disease Relevance 0 Pain Relevance 0
Seven of the eight are known to be significantly regulated in L5DRGs in rats following sciatic nerve transection (Gal, Pacap, Cchl2a, Sprr1a, C-Jun, Trpv1 and Scn11a) while one is not regulated (Mmpcp1; [2]).
Localization (transection) of C-Jun in sciatic nerve associated with sciatic nerve
14) Confidence 0.16 Published 2009 Journal Mol Pain Section Body Doc Link PMC2649910 Disease Relevance 0.35 Pain Relevance 0.26
B (p65 subunit) and AP-1 (c-Fos) were then measured from 8 ?
Localization (measured) of AP-1
15) Confidence 0.14 Published 2010 Journal Part Fibre Toxicol Section Body Doc Link PMC2861012 Disease Relevance 0.16 Pain Relevance 0.13
Hypoxia was further shown to cause decreased expression of Toll-like receptor 4 receptors by inhibiting translocation of activator protein 1 [36] and caused suppression of Escherichia coli-induced nuclear factor ?
Localization (translocation) of activator protein 1 associated with hypoxia
16) Confidence 0.10 Published 2005 Journal PLoS Biology Section Body Doc Link PMC1088279 Disease Relevance 1.32 Pain Relevance 0.23
While some Wnt pathway targets (Myc and Plau) displayed elevated expression, other known targets (c-jun, cycD and Fosl1) did not.
Localization (targets) of c-jun
17) Confidence 0.09 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2529338 Disease Relevance 0 Pain Relevance 0.04
Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.
Localization (release) of immediate-release associated with pain, oxycodone and cancer pain
18) Confidence 0.03 Published 1998 Journal J. Clin. Oncol. Section Title Doc Link 9779696 Disease Relevance 0.10 Pain Relevance 0.67
METHODS: Medical and pharmacy claims from the PharMetrics' Patient-Centric Database were used to identify opioid-naïve patients who received a new prescription for oxycodone- or hydrocodone-containing immediate-release oral products between 2002 and 2006.
Localization (elease ) of immediate-release
19) Confidence 0.02 Published 2010 Journal Ann Pharmacother Section Body Doc Link 20197473 Disease Relevance 0 Pain Relevance 0
Three RCTs demonstrated similar rates of efficacy between OD tramadol and immediate-release (IR) or sustained-release (SR) formulations, with a better adverse events profile.
Localization (release) of immediate-release associated with tramadol
20) Confidence 0.01 Published 2007 Journal Therapeutics and Clinical Risk Management Section Abstract Doc Link PMC2376086 Disease Relevance 0.53 Pain Relevance 1.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox